Tirofiban (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.
Cell Experiment | |
---|---|
Cell lines | |
Preparation method | |
Concentrations | |
Incubation time |
Animal Experiment | |
---|---|
Animal models | Adult mongrel dogs |
Formulation | In saline |
Dosages | ~500 mg/kg |
Administration | I.P. |
Molecular Weight | 440.6 |
Formula | C22H36N2O5S |
CAS Number | 144494-65-5 |
Form | Solid |
Solubility (25°C) | DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Lukasz Szarpak, et al. Tirofiban in emergency conditions
[3] Scott D Nei, et al. Tirofiban in Suspected Left Ventricular Assist Device Pump Thrombosis
[4] Wei Li, et al. Intravenous tirofiban therapy for patients with capsular warning syndrome
Related Integrin Products |
---|
HSDVHK-NH2
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
LDV
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
Obtustatin
Obtustatin is a non-RGD disintegrin of 41 residues. |
Integrin Binding Peptide
Integrin Binding Peptide is derived by fibronectin. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.